About: A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 December 2006

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) bài báo khoa học (vi) наукова стаття, опублікована в грудні 2006 (uk) artículu científicu espublizáu n'avientu de 2006 (ast) scientific article published on 01 December 2006 (en)
publication date	wds:Q79405030-7826A8E7-FAA1-4718-BF0F-1E4D1FEDEE25
publication date	2006-12-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q79405030-F54FA1FC-F07F-4903-AF98-78FDB885E2F1
language of work or name	English
author name string	wds:Q79405030-022FF06E-4247-433C-BB7B-305D0C6AF53E wds:Q79405030-187D240B-BC1B-4A9E-A263-F68395BC273D wds:Q79405030-342867B4-FE88-42DA-B377-C2E1A61392E3 wds:Q79405030-4ADB441A-E0F4-4C79-92EB-445133C81ABC wds:Q79405030-599DDBC7-A34B-4506-AE0F-7B71DC9FF02F wds:Q79405030-6EF5371D-3EFB-4A9E-9A60-38A021B5621F wds:Q79405030-9E5826C7-2A89-4957-AC55-F99019E50416 wds:Q79405030-B01FB9DC-C8DE-4B6C-A2FE-EA88A1D01BC1 wds:Q79405030-B6512BF8-103B-4566-BF1F-30AEBDC7ED95 wds:Q79405030-C41FA13E-90DD-480C-A28B-23B19A39F021 wds:Q79405030-C5011DF9-23D8-434A-85F9-9E3BB9B34171 wds:Q79405030-E3E586FC-777B-439D-883B-F5D39DAA497E wds:Q79405030-F92204F0-68F5-4081-80C7-9762F629DF7F
author name string	Lei Chen John P Leonard John C Byrd Christos Emmanouilides Don M Benson Pierluigi Porcu Pablo Garcia Charles F Eisenbeis Khuda D Khan Glenn Michelson Sandra Milan Amy L Banks Lawrence Piro
rdfs:label	A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma (en) A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma (nl)
skos:prefLabel	A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma (en) A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma (nl)
name	A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma (en) A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma (nl)
author	wds:Q79405030-0BFDACB5-8298-4415-B4C0-E1DD5BCFCE2A wds:Q79405030-C617B3D3-645C-46C8-B8E5-5CEEC4CF68ED wds:Q79405030-f1a396f6-4bfb-8236-d487-3e0c1e903fa3
author	Amy K. Ferketich Michael A Caligiuri Deborah Hurst
title	wds:Q79405030-3CBBB235-8E3A-4B94-AFDA-DD36BD6BECF5
title	A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma (en)
page(s)	wds:Q79405030-23750BC2-CB4F-4B3A-B7A9-276DCF964131
page(s)	7046-7053
instance of	wds:Q79405030-60FFA093-00CD-4813-9F8E-A8649B5A8A29
instance of	scholarly article
main subject	wds:Q79405030-8C78CCB8-5A17-440E-8B45-55C5AA651BC1
main subject	rituximab
PubMed ID	wds:Q79405030-325A7F7A-5267-43FC-9130-50B25191A1FE
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17145827
PubMed ID	17145827
published in	wds:Q79405030-F9E6F2FF-9265-4672-B1BD-C26D770591E5
published in	Clinical Cancer Research
issue	wds:Q79405030-6EB18E2D-C947-457F-93FD-3E0FDD465865
volume	wds:Q79405030-D58578F2-179E-4121-9247-D87E2AE741DC
issue	23
volume	12
DOI	wds:Q79405030-55946B1C-EE31-4282-8BC0-07D3AD3D851C
DOI	http://dx.doi.org/10.1158/1078-0432.CCR-06-1571
DOI	10.1158/1078-0432.CCR-06-1571
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q79405030
is cites work of	Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity Rituximab resistance Recent advances in the field of anti-cancer immunotherapy Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma Monoclonal antibodies: versatile platforms for cancer immunotherapy Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies Monoclonal antibodies for the treatment of cancer Novel immunotherapeutic strategies of gastric cancer treatment Advantages and clinical applications of natural killer cells in cancer immunotherapy Natural killer cell-directed therapies: moving from unexpected results to successful strategies Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance Thalidomide and rituximab in Waldenstrom macroglobulinemia Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells Immunotherapy of cancer Human natural killer cells Combination strategies to enhance antitumor ADCC. The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells Allogeneic natural killer cells for refractory lymphoma Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma models Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism Follicular Lymphoma: The Role of the Tumor Microenvironment in Prognosis The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Toll-like Receptor 4 Ligands Down-regulate Fcγ Receptor IIb (FcγRIIb) via MARCH3 Protein-mediated Ubiquitination

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software